Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States DOI Creative Commons
Mark A. Schmidt, Maxim Blum,

Judy Donald

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 8, 2025

Invasive Escherichia coli disease (IED) incidence has increased over recent years among aging populations and rising antimicrobial resistance. Here, we report on a comparative, cross-sectional, retrospective analysis of US patients with IED to quantify IED-related healthcare resource utilization (HCRU), costs, impact health-related quality life (HRQoL). This study included Kaiser Permanente Northwest (KPNW) members aged ≥ 60 enrolled between July 2019 January 2020. Patients were divided into three groups: Group 1 had experienced episode (≤ 3 weeks before enrollment); 2 former (13–18 months was at risk no prior history IED. Data collected from electronic hospital records, patient survey, the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Mean costs adjusted according individual follow-up. Patient characteristics generally consistent across Groups (n = 289), 319), 340). Inpatient hospitalization observed in 84%, 44%, 15% 1, 3, respectively. direct per (per 30-day follow-up) $17,168, $2530, $1094 2, total year following an (Group 2) $35,034 vs. $16,163 at-risk 3. HRQoL poor for IED, mean EQ-5D-5L utility index value 0.25 worst day illness. During 12-month follow-up period, rehospitalization rates number antibiotic prescriptions ~ threefold higher who recovered those risk. These data demonstrate substantial short- long-term impacts HCRU, HRQoL. Additional research is needed further novel prevention strategies.

Language: Английский

Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States DOI Creative Commons
Mark A. Schmidt, Maxim Blum,

Judy Donald

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 8, 2025

Invasive Escherichia coli disease (IED) incidence has increased over recent years among aging populations and rising antimicrobial resistance. Here, we report on a comparative, cross-sectional, retrospective analysis of US patients with IED to quantify IED-related healthcare resource utilization (HCRU), costs, impact health-related quality life (HRQoL). This study included Kaiser Permanente Northwest (KPNW) members aged ≥ 60 enrolled between July 2019 January 2020. Patients were divided into three groups: Group 1 had experienced episode (≤ 3 weeks before enrollment); 2 former (13–18 months was at risk no prior history IED. Data collected from electronic hospital records, patient survey, the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Mean costs adjusted according individual follow-up. Patient characteristics generally consistent across Groups (n = 289), 319), 340). Inpatient hospitalization observed in 84%, 44%, 15% 1, 3, respectively. direct per (per 30-day follow-up) $17,168, $2530, $1094 2, total year following an (Group 2) $35,034 vs. $16,163 at-risk 3. HRQoL poor for IED, mean EQ-5D-5L utility index value 0.25 worst day illness. During 12-month follow-up period, rehospitalization rates number antibiotic prescriptions ~ threefold higher who recovered those risk. These data demonstrate substantial short- long-term impacts HCRU, HRQoL. Additional research is needed further novel prevention strategies.

Language: Английский

Citations

1